Suggested Readings

From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection.

Ridker PM. Circ Res. 2016;118(1):145-56.

Antiinflammatory therapy with canakinumab for atherosclerotic disease.

Ridker PM, et al. N Engl J Med. 2017;377(12):1119-1131.

Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.

Hoogeveen RM, et al. Sci Rep. 2021;11(1):4126.

Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease.

Ridker PM, et al. Circ Res. 2021 May 28;128(11):1728-1746.

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.

Ridker PM, et al. Lancet. 2021;397(10289):2060-2069.

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

Ridker PM. Cardiovasc Res. 2021;117(11):e138-e140.

Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial.

Wada Y, et al. J Cardiol. 2023;82(4):279-285.

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

Rossing P, et al. Nephrol Dial Transplant. 2023;38(9):2041-2051.

Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE).

Pergola PE, et al. J Am Soc Nephrol. 2024;35(1):74-84.

Linked Resources

CLINICAL PRACTICE GUIDELINES AND STATEMENTS

Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association.

Khan SS, et al. Circulation. 2023;148(24):1982-2004.

A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association.

Ndumele CE, et al. Circulation. 2023;148(20):1636-1664. 

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024;105(4S):S117-S314.

Related activities
Webcast Series 
0.50 AMA PRA

Exploring the Link Between Systemic Inflammation, Atherosclerosis, and CKD

Module 1

Faculty: Paul M. Ridker, MD, MPH ; Katherine R. Tuttle, MD, FASN, FACP, FNKF
Release: 08/30/2024
Expiration: 08/30/2025
Begin Activity
Webcast Series 
0.50 AMA PRA

Management of ASCVD in Patients with CKD: Present, Past, and Future

Module 2

Faculty: Paul M. Ridker, MD, MPH ; Katherine R. Tuttle, MD, FASN, FACP, FNKF
Release: 08/30/2024
Expiration: 08/30/2025
Begin Activity